BioSpace News Archive

Crown Aesthetics, a Crown Laboratories, Inc. company, announced that its groundbreaking clinical study, recently accepted for publication in the Journal of Clinical and Aesthetic Dermatology, has further shed light on the significant role its skin-biome care product line, BIOJUVE™, may have in the advancement of the practice of dermatology.

Inhibitor Therapeutics, Inc. has entered into an exclusive, worldwide licensing agreement with Johns Hopkins University for their U.S Patent 8,980,930 “New Angiogenesis Inhibitors”.

Implement a waste-to-energy strategy to divert from landfills’ waste from several of our laboratory locations by 2025.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology.

Codexis, Inc. announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, whereby Aldevron will acquire a global exclusive license to Codexis’ Codex® HiCap RNA Polymerase.

Veru Inc. announced that it has commenced an underwritten public offering of shares of its common stock.

Vir Biotechnology, Inc. announced strategic imperatives to focus its capital allocation on programs with the highest potential for patient impact and value creation.

10x Genomics, Inc. announced that a new non-peer-reviewed study has independently evaluated the technical performance of three spatial imaging platforms and found the Xenium In Situ platform demonstrated higher quality transcript counts per gene at higher specificity for 22 formalin-fixed paraffin-embedded tissues compared to NanoString’s CosMx and Vizgen’s MERSCOPE.

Novanta Inc. (Nasdaq: NOVT) (the “Company”) announced today that Robert Buckley, Chief Financial Officer, Chuck Ravetto, Group President, and Ray Nash, Vice President, Corporate Finance, are scheduled to present at the CJS Securities 24th Annual New Ideas for the New Year Investor Conference on Wednesday, January 10, 2024, which is being held virtually.

MAPS Public Benefit Corporation (MAPS PBC) formally submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) which included data from two published Phase 3 studies as well as numerous earlier trials.